Kamada (KMDA) Other Non-Current Liabilities (2021 - 2026)
Kamada's (KMDA) quarterly Other Non-Current Liabilities came in at $29.9 million in Q1 2026, down 9.29% YoY from $33.0 million in Q1 2025, and down 0.62% on a QoQ basis from $30.1 million in Q4 2025.
Kamada (KMDA) Other Non-Current Liabilities (2021 - 2026) Analysis & Trends
Kamada (KMDA) has 6 years of Other Non-Current Liabilities data on file, last reported at $29.9 million in Q1 2026.
- Quarterly Other Non-Current Liabilities fell 9.29% year-over-year to $29.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $29.9 million (down 9.29% YoY) and the FY2025 annual result came in at $30.1 million, down 8.24% from the prior year.
- Other Non-Current Liabilities retreated to $29.9 million in Q1 2026, from $30.1 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $42.5 million in Q1 2022 to a low of $37280.0 in Q1 2023.
- A 5-year average of $30.8 million and a median of $34.1 million in 2024 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2023 — Other Non-Current Liabilities slumped 99.91% — and 2024, when it soared 93360.3%.
- Tracing KMDA's Other Non-Current Liabilities over 5 years: stood at $37.3 million in 2022, then declined by 7.85% to $34.4 million in 2023, then fell by 4.55% to $32.8 million in 2024, then declined by 8.24% to $30.1 million in 2025, then slipped by 0.62% to $29.9 million in 2026.
- The last three Other Non-Current Liabilities figures came in at $29.9 million (Q1 2026), $30.1 million (Q4 2025), and $32.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | Kamada | 463.48 Mn | 434.00 Mn | 22.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 28.96 Mn |
| Mar 31, 2026 | 29.93 Mn |
| Dec 31, 2025 | 30.11 Mn |
| Sep 30, 2025 | 32.54 Mn |
| Jun 30, 2025 | 32.78 Mn |
| Mar 31, 2025 | 32.99 Mn |
| Dec 31, 2024 | 32.82 Mn |
| Sep 30, 2024 | 34.12 Mn |
| Jun 30, 2024 | 34.24 Mn |
| Mar 31, 2024 | 34.84 Mn |
| Dec 31, 2023 | 34.38 Mn |
| Sep 30, 2023 | 36.48 Mn |
| Jun 30, 2023 | 36.51 Mn |
| Mar 31, 2023 | 37,280.00 |
| Dec 31, 2022 | 37.31 Mn |
| Sep 30, 2022 | 39,915.00 |
| Jun 30, 2022 | 41.30 Mn |
| Mar 31, 2022 | 42.53 Mn |
| Dec 31, 2021 | 43.93 Mn |